Leukemia
This journal publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction and molecular targets for therapy.
TSLPR CAR T-cell therapy: A new hope for CRLF2+ ALL, but timing of JAK inhibition is crucial
Acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements in Ph-like and Down syndrome-associated ALL subtypes poses a significant challenge in pediatric oncology. These genetic abnormalities lead to constitutive signaling activation and induce resistance to conventional chemotherapy.
VEXAS Syndrome: Hope, Challenges, Solutions, and the Road Ahead
This post aims to raise awareness, build understanding, and inspire action within the medical and patient communities alike. The road is long, but with continued collaboration and innovation, we can offer new hope to those affected by VEXAS syndrome.
Mutation in Bruton Tyrosine Kinase (BTK) A428D Confers Resistance To BTK-Degrader Therapy In Chronic Lymphocytic Leukemia
Drugs that target BTK for proteasomal degradation, so-call BTK degraders, are presumed able to mitigate the risk of drug resistance due to BTK mutations. In Leukemia 38:1818 (2024), Kipps and colleagues describe a patient who developed resistance to the BTK-degrader BGB-16673 via a mutation in BTK.
